ADL-5859
![]() | |
Names | |
---|---|
IUPAC name
N,N-Diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide
| |
Identifiers | |
PubChem CID
|
|
Properties | |
C24H28N2O3 | |
Molar mass | 392.499 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
ADL-5859, also known as compound 20, is an opioid drug that is selective for the δ-opioid receptor, it is being investigated as an alternative to traditional opioids in pain management.
Mechanism of action
[edit]Like all opioid drugs, ADL-5859 activates opioid receptors, but where as traditional opioids (such as oxycodone) activate the three main receptors (mu, delta, and kappa), ADL-5859 appears to be selective and only activates the delta receptor.[1] with a Ki of 20 nM
Therapeutic potential
[edit]Like other opioids, it has potential in pain management; however, by being selective for the delta receptor, multiple undesirable side effects of traditional opioids are not present, such as respiratory depression, sedation, and euphoria.
ADL-5859 was also found to be orally active, which makes it easier to administer.[2]
Multiple tests have shown its efficacy as an analgesic.[3][1] It also did not seem to be a convulsant, unlike some other delta agonist opioids.[4]
References
[edit]- ^ a b Spahn, Viola; Stein, Christoph (February 2017). "Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development". Expert Opinion on Investigational Drugs. 26 (2): 155–160. doi:10.1080/13543784.2017.1275562. ISSN 1744-7658. PMID 28001096.
- ^ Le Bourdonnec, Bertrand; Windh, Rolf T.; Ajello, Christopher W.; Leister, Lara K.; Gu, Minghua; Chu, Guo-Hua; Tuthill, Paul A.; Barker, William M.; Koblish, Michael; Wiant, Daniel D.; Graczyk, Thomas M.; Belanger, Serge; Cassel, Joel A.; Feschenko, Marina S.; Brogdon, Bernice L. (2008-10-09). "Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859)". Journal of Medicinal Chemistry. 51 (19): 5893–5896. doi:10.1021/jm8008986. ISSN 1520-4804. PMID 18788723.
- ^ Nozaki, Chihiro; Le Bourdonnec, Bertrand; Reiss, David; Windh, Rolf T.; Little, Patrick J.; Dolle, Roland E.; Kieffer, Brigitte L.; Gavériaux-Ruff, Claire (September 2012). "δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization". The Journal of Pharmacology and Experimental Therapeutics. 342 (3): 799–807. doi:10.1124/jpet.111.188987. ISSN 1521-0103. PMC 3422521. PMID 22700431.
- ^ Chung, Paul Chu Sin; Boehrer, Annie; Stephan, Aline; Matifas, Audrey; Scherrer, Grégory; Darcq, Emmanuel; Befort, Katia; Kieffer, Brigitte L. (2015-02-01). "Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures". Behavioural Brain Research. 278: 429–434. doi:10.1016/j.bbr.2014.10.029. ISSN 1872-7549. PMC 4382405. PMID 25447299.